69 related articles for article (PubMed ID: 22915660)
1. Role of androgens in abiraterone resistance.
Colloca G
J Clin Oncol; 2012 Oct; 30(28):3561-2: author reply 3562. PubMed ID: 22915660
[No Abstract] [Full Text] [Related]
2. Molecular states underlying androgen receptor activation: a framework for therapeutics targeting androgen signaling in prostate cancer.
Nelson PS
J Clin Oncol; 2012 Feb; 30(6):644-6. PubMed ID: 22184375
[No Abstract] [Full Text] [Related]
3. Effects of abiraterone acetate on androgen signaling in castrate-resistant prostate cancer in bone.
Efstathiou E; Titus M; Tsavachidou D; Tzelepi V; Wen S; Hoang A; Molina A; Chieffo N; Smith LA; Karlou M; Troncoso P; Logothetis CJ
J Clin Oncol; 2012 Feb; 30(6):637-43. PubMed ID: 22184395
[TBL] [Abstract][Full Text] [Related]
4. Abiraterone acetate for the treatment of prostate cancer.
Ryan CJ; Cheng ML
Expert Opin Pharmacother; 2013 Jan; 14(1):91-6. PubMed ID: 23199349
[TBL] [Abstract][Full Text] [Related]
5. Overcoming persistent dependency on androgen signaling after progression to castration-resistant prostate cancer.
Yamaoka M; Hara T; Kusaka M
Clin Cancer Res; 2010 Sep; 16(17):4319-24. PubMed ID: 20647476
[TBL] [Abstract][Full Text] [Related]
6. Abiraterone acetate (Zytiga) for metastatic castration-resistant prostate cancer.
Med Lett Drugs Ther; 2011 Aug; 53(1370):63-4. PubMed ID: 21836546
[No Abstract] [Full Text] [Related]
7. Re: AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer.
Anand AU; Bjartell A
Eur Urol; 2015 Feb; 67(2):349-50. PubMed ID: 25760252
[No Abstract] [Full Text] [Related]
8. Re: AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer.
Taneja SS
J Urol; 2015 Feb; 193(2):538. PubMed ID: 25617272
[No Abstract] [Full Text] [Related]
9. Abiraterone and novel antiandrogens: overcoming castration resistance in prostate cancer.
Ferraldeschi R; Pezaro C; Karavasilis V; de Bono J
Annu Rev Med; 2013; 64():1-13. PubMed ID: 23020876
[TBL] [Abstract][Full Text] [Related]
10. Formation of AR-SMRT binding in prostate cancer cells treated with natural histone deacetylase inhibitor.
Trtková K; Pašková L; Matiješčuková N; Kolář Z
Cancer Biomark; 2010; 7(2):79-90. PubMed ID: 21178266
[TBL] [Abstract][Full Text] [Related]
11. Chromogranin A predicts outcome in prostate cancer patients treated with abiraterone.
Burgio SL; Conteduca V; Menna C; Carretta E; Rossi L; Bianchi E; Kopf B; Fabbri F; Amadori D; De Giorgi U
Endocr Relat Cancer; 2014 Jun; 21(3):487-93. PubMed ID: 24741024
[TBL] [Abstract][Full Text] [Related]
12. Abiraterone acetate is well tolerated without concomitant use of corticosteroids.
Attard G; Reid AH; de Bono JS
J Clin Oncol; 2010 Oct; 28(29):e560-1; author reply e562. PubMed ID: 20805462
[No Abstract] [Full Text] [Related]
13. Abiraterone acetate for castration resistant prostate cancer.
Shah S; Ryan C
Expert Opin Investig Drugs; 2010 Apr; 19(4):563-70. PubMed ID: 20225998
[TBL] [Abstract][Full Text] [Related]
14. Abiraterone. Cougar Biotechnology.
Madan RA; Arlen PM
IDrugs; 2006 Jan; 9(1):49-55. PubMed ID: 16374734
[TBL] [Abstract][Full Text] [Related]
15. Abiraterone acetate, a first-in-class CYP17 inhibitor, establishes a new treatment paradigm in castration-resistant prostate cancer.
Bedoya DJ; Mitsiades N
Expert Rev Anticancer Ther; 2012 Jan; 12(1):1-3. PubMed ID: 22149426
[No Abstract] [Full Text] [Related]
16. Use of abiraterone for prostate cancer.
Mohler JL; Pantuck AJ
J Urol; 2011 Mar; 185(3):783-6. PubMed ID: 21239011
[No Abstract] [Full Text] [Related]
17. Abiraterone in prostate cancer.
Ryan C
Clin Adv Hematol Oncol; 2010 Nov; 8(11):761-2. PubMed ID: 21326154
[No Abstract] [Full Text] [Related]
18. Interactions of abiraterone, eplerenone, and prednisolone with wild-type and mutant androgen receptor: a rationale for increasing abiraterone exposure or combining with MDV3100.
End D; Molina A; Todd M; Meyers ML
Cancer Res; 2013 May; 73(9):2926. PubMed ID: 23610449
[No Abstract] [Full Text] [Related]
19. Abiraterone and increased survival in metastatic prostate cancer.
Sonpavde G
N Engl J Med; 2011 Aug; 365(8):766-7; author reply 767-8. PubMed ID: 21864181
[No Abstract] [Full Text] [Related]
20. Testosterone boosts for treatment of castration resistant prostate cancer: an experimental implementation of intermittent androgen deprivation.
Thelen P; Heinrich E; Bremmer F; Trojan L; Strauss A
Prostate; 2013 Nov; 73(15):1699-709. PubMed ID: 23868789
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
